Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy

Uwe Klaus Zettl, Ulrike Bauer-Steinhusen, Thomas Glaser, Klaus Hechenbichler, Michael Hecker, Study Group, Uwe Klaus Zettl, Ulrike Bauer-Steinhusen, Thomas Glaser, Klaus Hechenbichler, Michael Hecker, Study Group

Abstract

Background: Due to the preventive nature of disease-modifying therapies for multiple sclerosis, treatment success particularly depends on adherence to therapeutic regimens and patients' perception of treatment efficacy. The latter is strongly influenced by the confidence in the involved health care professionals and the relationship to the treating physician.

Methods: In this report, we considered physicians' and patients' evaluation of satisfaction with interferon beta-1b treatment efficacy for assessing the congruence in ratings. Data were queried in a study conducted between 2009 and 2013.

Results: After 6 months of therapy, > 80 % of the patients and physicians (N = 445) showed high degrees of satisfaction regarding interferon beta-1b treatment, with only few physicians and patients (≤2.0 %) rating "not satisfied". The proportion of patients rating with the same category as their physicians was similar after 6 months (47 % congruence) and at the 24 months/study end visit (49 %). Discrepancies between ratings were observed with respect to study end: for patients with premature study end, more patients and physicians rated being not satisfied with the therapy, accompanied by a considerably lower congruence of 33 % compared to 54 % for patients receiving the therapy for at least 2 years and completing the study regularly.

Conclusions: Regular communication between physicians and patients about their perception of therapy might improve alignment of treatment evaluation and could result in increased therapy persistence. In addition, patients' willingness to perform a long-term therapy - even in the absence of disease symptoms - might be promoted by repeated exchange between health care providers and patients with regard to realistic treatment expectations.

Trial registration: ClinicalTrials.gov NCT00902135 (registered May 13, 2009).

Keywords: Interferon beta-1b; Multiple Sclerosis; Patient-Physician Relationship; Therapy Adherence; Treatment Satisfaction.

Figures

Fig. 1
Fig. 1
Satisfaction with interferon beta-1b therapy. a Physicians' and patients’ ratings of the therapy 6 months after the start of treatment as documented by the physicians in case report forms (CRF) and by the patients in a separate questionnaire. b Physicians' and patients’ ratings of the therapy at the final visit (24 months/study end), with substratification for patients with regular or premature study termination. pat. = patients; phys. = physicians; quest. = questionnaire
Fig. 2
Fig. 2
Congruence of physicians’ and patients’ evaluation of the therapy. Comparison of physicians’ and patients’ ratings of the interferon beta-1b therapy for multiple sclerosis (a) at the 6 months visit and (b) at the 24 months visit/study end, substratified for (c) regular and (d) premature study termination. CRF = case report forms; shaded areas = proportion of congruent ratings of patients and physicians

References

    1. Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72:132–41. doi: 10.1159/000360528.
    1. Reder AT, Oger JF, Kappos L, O'Connor P, Rametta M. Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis. Mult Scler Relat Disord. 2014;3:294–302. doi: 10.1016/j.msard.2013.11.005.
    1. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89:225–40. doi: 10.1016/j.mayocp.2013.11.002.
    1. Ross AP. Tolerability, adherence, and patient outcomes. Neurology. 2008;71:S21–3. doi: 10.1212/WNL.0b013e31818f3dcb.
    1. Visser LH, van der Zande A. Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis. Eur J Neurol. 2011;18:1343–9. doi: 10.1111/j.1468-1331.2011.03411.x.
    1. Katsarava Z, Ehlken B, Limmroth V, Taipale K, Patel SN, Niemczyk G, et al. Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program. BMC Neurol. 2015;15:170. doi: 10.1186/s12883-015-0426-x.
    1. Yoshioka N, Ishii H, Tajima N, Iwamoto Y. DAWN Japan group. Differences in physician and patient perceptions about insulin therapy for management of type 2 diabetes: the DAWN Japan study. Curr Med Res Opin. 2014;30:177–83. doi: 10.1185/03007995.2013.855187.
    1. Coyle PK, Cohen BA, Leist T, Markowitz C, Oleen-Burkey M, Schwartz M, et al. Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes. BMC Neurol. 2014;14:49. doi: 10.1186/1471-2377-14-49.
    1. Street RL, Jr, Elwyn G, Epstein RM. Patient preferences and healthcare outcomes: an ecological perspective. Expert Rev Pharmacoecon Outcomes Res. 2012;12:167–80. doi: 10.1586/erp.12.3.
    1. Zettl UK, Bauer-Steinhusen U, Glaser T, Hechenbichler K, Limmroth V, Study Group Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study. BMC Neurol. 2013;13:117. doi: 10.1186/1471-2377-13-117.
    1. Zettl UK, Bauer-Steinhusen U, Glaser T, Czekalla J, Hechenbichler K, Limmroth V, et al. Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary. Adv Ther. 2016;33:834–47. doi: 10.1007/s12325-016-0325-6.
    1. Lugaresi A, Rottoli MR, Patti F. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Rev Neurother. 2014;14:1029–42. doi: 10.1586/14737175.2014.945523.
    1. Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256:568–76. doi: 10.1007/s00415-009-0096-y.
    1. Kern S, Reichmann H, Ziemssen T. Adherence to neurologic treatment. Lessons from multiple sclerosis. Nervenarzt. 2008;79:877–90. doi: 10.1007/s00115-008-2419-0.
    1. Bensmail D, Hanschmann A, Wissel J. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians) J Med Econ. 2014;17:618–25. doi: 10.3111/13696998.2014.925462.
    1. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18:69–77. doi: 10.1111/j.1468-1331.2010.03110.x.
    1. Mohr DC, Goodkin DE, Likosky W, Gatto N, Neilley LK, Griffin C, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler. 1996;2:222–6.
    1. Koudriavtseva T, Onesti E, Pestalozza IF, Sperduti I, Jandolo B. The importance of physician-patient relationship for improvement of adherence to long-term therapy: data of survey in a cohort of multiple sclerosis patients with mild and moderate disability. Neurol Sci. 2012;33:575–84. doi: 10.1007/s10072-011-0776-0.
    1. Smrtka J, Caon C, Saunders C, Becker BL, Baxter N. Enhancing adherence through education. J Neurosci Nurs. 2010;42:S19–29. doi: 10.1097/JNN.0b013e3181ef82b6.
    1. Mohr DC, Goodkin DE, Masuoka L, Dick LP, Russo D, Eckhardt J, et al. Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Mult Scler. 1999;5:192–7. doi: 10.1177/135245859900500309.
    1. Okie S. The evolving primary care physician. N Engl J Med. 2012;366:1849–53. doi: 10.1056/NEJMp1201526.
    1. Jongen PJ, Lemmens WA, Hupperts R, Hoogervorst ELJ, Schrijver HM, Slettenaar A, et al. Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines. Patient Prefer Adherence. 2016;10:909–17. doi: 10.2147/PPA.S108121.
    1. Kohlmann T, Wang C, Lipinski J, Hadker N, Caffrey E, Epstein M, et al. The impact of a patient support program for multiple sclerosis on patient satisfaction and subjective health status. J Neurosci Nurs. 2013;45:E3–14. doi: 10.1097/JNN.0b013e31828a4161.
    1. Lorefice L, Mura G, Coni G, Fenu G, Sardu C, Frau J, et al. What do multiple sclerosis patients and their caregivers perceive as unmet needs? BMC Neurol. 2013;13:177. doi: 10.1186/1471-2377-13-177.
    1. Batbaatar E, Dorjdagva J, Luvsannyam A, Savino MM, Amenta P. Determinants of patient satisfaction: a systematic review. Perspect Public Health. 2016
    1. Everett CM, Morgan P, Jackson GL. Primary care physician assistant and advance practice nurses roles: Patient healthcare utilization, unmet need, and satisfaction. Healthc (Amst) 2016
    1. Menning M, Twork S, Kugler J. Adherence, self-efficacy, physician visits in a clinical trial over 6 months in multiple sclerosis patients. Gesundheitswesen. 2011;73:e84–8. doi: 10.1055/s-0030-1255055.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe